IBO - Impact BioMedical Inc Debt to Book Capitalization Ratio

The distribution of debt capital within the balance sheet capitalization on this GURU.Markets chart demonstrates a liquidity deficit for Impact BioMedical Inc (IBO) due to a lack of sales and early-stage research. The value 0.00 characterizes this valuation parameter, which is further complicated by logistics disruptions and sanction barriers for exports. The risks of resource fragmentation across various niches and the need for investment threaten the holding's margins.

Impact BioMedical, Inc. - IBO Debts to Book Capitalization (period 09/17/2024 - 10/27/2026)

Impact BioMedical Inc (IBO) focuses on biomedical research while maintaining a minimal environmental footprint. This metric compares total liabilities to net assets, determining the extent to which equity covers debt. A decrease in this value indicates financial stability, while an increase signals bankruptcy risk. By analyzing the debt-to-book capitalization ratio of Impact BioMedical Inc (IBO), investors can gauge the real-time market reaction. This chart reflects the balance between debt-funded expansion and solvency.

Competitors of Impact BioMedical Inc

Debt to Book Capitalization Ratio Haleon plc|kenvue.com - Debt to Net Assets Ratio|VRNA: Debt to Book Capitalization Ratio|MENS - Debt to Book Value|LGND: Debts to Book Capitalization|Debts to Book Capitalization Amneal Corp|PRGO - Debt to Book Value|Debt to Net Assets Ratio ALVO|Liquidia - Debt to Book Capitalization Ratio|Debts to Book Value Galapagos N.V. GLPG|Debt to Book Value ANI Pharma (ANIP)|Debt to Book Capital Afrezza MNKD|Debts to Book Capitalization Amphastar Pharmaceuticals (AMPH)|PCRX - Debt to Net Assets Ratio|Debts to Book Capitalization SPRY|TBPH (Theravance Biopharma Inc) - Debts to Book Value|AQST - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio scPharma|TECX (Tectonic Therapeutic, Inc.) - Debts to Book Capitalization|Debts to Net Assets TNXP (tonixpharma.com)|China SXT Pharmaceuticals, Inc. - Debt to Book Capitalization Ratio|Eupraxia Pharmaceuticals, Inc. - Debt to Book Value|Debt to Book Capitalization Ratio BioHarvest|EXOZ - Debts to Book Capitalization Ratio|ORMP: Debts to Book Capitalization|Entera Bio (ENTX) - Debts to Book Capitalization|Debts to Book Capitalization HYFT|Debt to Book Value ABVC BioPharma Inc. (ABVC)|Debt to Book Value Cumberland Pharma|Debt to Book Capital Quantum BioPharma Corp QNTM|Debt to Book Value FibroGen, Inc.|Debt to Net Assets Ratio telomirpharma.com TELO|RANI - Debts to Book Capitalization|SNYR - Debt to Book Capitalization Ratio|rallybio.com - Debts to Book Capitalization|LEXX (Lexaria Bioscience Corp.) - Debts to Net Assets|Debt to Book Capitalization Ratio PULM (Pulmatrix, Inc.)|Debts to Book Value PTHL|Debt to Book Capitalization Ratio APM (Aptorum Group Limited)|Debt to Book Value Lyra Therapeutics Inc. (LYRA)|TNFA: Debts to Book Capitalization|Debts to Book Value cbdMD Inc. YCBD|PainReform Ltd. (PRFX) - Debts to Book Capitalization|CYTO - Debt to Book Value Ratio|Lipella Pharmaceuticals, Inc. - Debts to Book Capitalization|OptiNose Inc (OPTN) - Debts to Net Assets|Debts to Book Capitalization PIRS|Debt to Book Value Procaps Group Corp|Debts to Book Capitalization PTPI|Debts to Book Capitalization QLI (qlsyy.net)|Debt to Book Capitalization Ratio ACELYRIN SLRN|TFFP - Debt to Book Capitalization Ratio